分化型甲状腺癌131I全身显像和治疗条件探讨

Condition of Patient with Well-differentiated Thyroid Cancer for 131I Scintigraphy or Therapy

  • 摘要: 回顾性分析了 142例分化型甲状腺癌病例,所有病人均接受甲状腺近全切除术,以评价分化型甲状腺癌甲状腺全切术后和甲癌术后经 131 I去除残留组织后,用甲状腺素替代治疗病人半年复查时停服甲状腺素后 TSH升高的最佳时间。将 142例分为两组,一组为近期手术后未即刻给予甲状腺素替代治疗,计划一个月后用 131 I去除残留组织者 ,共 83例 ;另一组为甲状腺全切,已经过 131 I去除处理后半年复诊病人,停止服用甲状腺素后拟行 131 I全身显像者共 59例。两组病人均在 2~ 4周时常规测定血中 TSH浓度,观察两组 TSH升高的程度。结果证实,手术后不用甲状腺素替代治疗组, TSH浓度 14~ 30天(平均 16天)为 15.8~ 145 mIU/L(平均 45.4 mIU/L), TSH浓度在 2周内超过 30 mIU/L的患者占 83%,在 3周内超过 30 mIU/L的占 86%, 3周以后占 88%。停止服用甲状腺激素组, TSH浓度 15~ 35天(平均 22天)为 21~ 92 mIU/L(平均为 60.1mIU/L),在 2周内> 30 mIU/L者占 87%, 3周内占 90%, 3周以后为 97%。以上结果提示,分化型甲癌患者绝大多数在 131 I全身显像和治疗前需做准备,但 2~ 3周后 80%以上的患者血中 TSH浓度> 30 mIU/L,达到全身显像和治疗所要求的水平。

     

    Abstract: To assess whether the patient preparation procedure for  131 I scintigraphy could be streamlined, the time course of TSH elevation were analysed after total thyroidectomy and after ablation thyroid remnants and the first follow up withdrawal thyroxine(T4) in patient with thyroid cancer. The clinical records of 142 patients with differentiated thyroid cancer were studied. All patients had undergoes total thyroidectomy. Two group patients were evaluated. The immediate postoperative group consisted 83 patients who were not given thyroid hormone replacement after surgery because of planned postoperative  131 I ablation thyroid remnants. The other group consisted of 59 patients in whom T4 replacement was stopped in preparation for whole body  131 I scintgraphy. The first TSH measurement and number of days were recorded after surgery or stopped thyroid hormone for each patient. In immediate postoperative group, TSH levels obtained 14 30 d (median 16 d) after surgery ranged from 15.8 to 145 mIU/L (median, 45.4 mIU/L). The TSH values exceed 30 mIU/L in 83% of patients evaluated at 2 weeks, in 86% of those evaluated at 3 weeks, and in 88% of those valuated after 3 weeks. In withdrawal T4 group, TSH levels obtained from 13 35 d (median 22 d), later ranged from 21 92 mIU/L (median, 60.1 mIU/L). The TSH values exceeded 30 mIU/L in 87% of patients evaluated at 2 weeks, in 90% of those evaluated at 3 weeks and in 97% of those valuated after 3 weeks. In most patients with thyroid cancer being prepared for  131 I imaging or therapy, a TSH level exceeding 30 mIU/L can be attained by withdrawal of thyroid hormone therapy 2 3 weeks, the duration of thyroxine withdrawal can be decreased to 3 weeks.

     

/

返回文章
返回